Comparative Fasting Bioavailability of 2 Different Betahistine Dihydrochloride 24-mg Tablets: A Single-Dose, Randomized-Sequence, Open-Label, 2-Period Crossover Study in Healthy Thai Volunteers
Objective: To evaluate the bioequivalence of 24 mg betahistine dihydrochloride tablets between the test product (Stei®) and the reference product (Serc®) in healthy Thai volunteers.
Methods: This was an open-label, randomized sequence, single-dose, two-period crossover study in 24 healthy volunteers. Half of the volunteers received a single dose of test product 24 mg and then reference product 24 mg after a minimum 7-day washout period. The remaining half of volunteers received the reference product first and then the test product with the same washout period. Blood samples were obtained at pre-dose and over 14 hours after dosing. Plasma concentrations of 2-pyridylacetic acid (2-PAA), a major metabolite of betahistine were quantified by using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Tolerability in volunteers was assessed during the study.
Results: Statistical comparison of the main pharmacokinetic parameters showed no significant difference between test and reference. The geometric mean ratios of 2-PAA between the test and reference products were 96.44%, 96.99%, and 94.56% for Cmax, AUC0-t, and AUC0-∞, respectively. These pharmacokinetic parameter values lie within the FDA and European Medicines Agency specified bioequivalence limit (80-125%). No serious adverse events related to the studied drugs were found.
Conclusion: It can be concluded that these two betahistine dihydrochloride products were considered bioequivalent.
Copyright (c) 2016 Siriraj Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Siriraj Medical Journal (SMJ) are protected by copyright. No material in this journal may be reproduced on any platform including electronic or in print or transmitted by any means, in whole or in part, without the prior written permission of the Editor of the SMJ. Written permission must also be obtained before any part of the SMJ is stored in any retrieval system of any nature.